{"disease":{"id":"streptococcal-infection-of-skin","name":"Streptococcal infection of skin","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"oritavancin","indication_name":"Streptococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orbactiv","generic_name":"ORITAVANCIN","company_name":"Melinta Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Lipoglycopeptide Antibacterial","quality_score":65,"revenue":null,"mechanism":"Orbactiv works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death."},{"drug_id":"orbactiv","indication_name":"Streptococcal infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Orbactiv","company_name":"Melinta Therapeutics, LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}